"Cardiovascular Diseases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Descriptor ID |
D002318
|
| MeSH Number(s) |
C14
|
| Concept/Terms |
Cardiovascular Diseases- Cardiovascular Diseases
- Cardiovascular Disease
- Disease, Cardiovascular
- Diseases, Cardiovascular
|
Below are MeSH descriptors whose meaning is more general than "Cardiovascular Diseases".
Below are MeSH descriptors whose meaning is more specific than "Cardiovascular Diseases".
This graph shows the total number of publications written about "Cardiovascular Diseases" by people in this website by year, and whether "Cardiovascular Diseases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 1 | 5 |
| 1997 | 7 | 0 | 7 |
| 1998 | 1 | 2 | 3 |
| 1999 | 4 | 4 | 8 |
| 2000 | 5 | 1 | 6 |
| 2001 | 2 | 1 | 3 |
| 2002 | 4 | 2 | 6 |
| 2003 | 6 | 6 | 12 |
| 2004 | 22 | 7 | 29 |
| 2005 | 11 | 8 | 19 |
| 2006 | 24 | 6 | 30 |
| 2007 | 31 | 7 | 38 |
| 2008 | 21 | 6 | 27 |
| 2009 | 32 | 11 | 43 |
| 2010 | 21 | 9 | 30 |
| 2011 | 37 | 14 | 51 |
| 2012 | 34 | 24 | 58 |
| 2013 | 39 | 11 | 50 |
| 2014 | 53 | 16 | 69 |
| 2015 | 50 | 14 | 64 |
| 2016 | 67 | 13 | 80 |
| 2017 | 43 | 15 | 58 |
| 2018 | 67 | 10 | 77 |
| 2019 | 74 | 13 | 87 |
| 2020 | 80 | 10 | 90 |
| 2021 | 87 | 10 | 97 |
| 2022 | 96 | 1 | 97 |
| 2023 | 94 | 3 | 97 |
| 2024 | 77 | 17 | 94 |
| 2025 | 66 | 13 | 79 |
| 2026 | 41 | 1 | 42 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiovascular Diseases" by people in Profiles.
-
Cardiovascular safety of psilocybin in psychiatric practice: a narrative review. Eur J Clin Pharmacol. 2026 Aug 01; 82(8).
-
End-of-Life Care in the Cardiovascular Intensive Care Unit. Cardiol Clin. 2026 Aug; 44(3):519-533.
-
Combination cardiometabolic therapy in type 2 diabetes: optimizing SGLT2 inhibitor and GLP-1 receptor agonist use. Curr Atheroscler Rep. 2026 Jul 18; 28(1).
-
Financial Toxicity: Inequities and Impact on Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2026 Aug; 46(8):e324015.
-
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. J Clin Oncol. 2026 Aug; 44(22):2140-2155.
-
Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline. Curr Atheroscler Rep. 2026 Jun 15; 28(1).
-
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. Circulation. 2026 Aug 04; 154(5):e188-e205.
-
2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026 Jul 28; 154(4):e50-e158.
-
Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2026 Aug 04; 88(5):589-612.
-
Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2026 Jul 28; 154(4):e159-e180.